Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by investment analysts at Oppenheimer Holdings, Inc. in a research report issued on Thursday. They currently have a $203.00 price objective on the medical research company’s stock. Oppenheimer Holdings, Inc.’s target price suggests a potential upside of 13.80% from the stock’s previous close.

Several other analysts have also commented on AMGN. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective on the stock. in a report on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC reissued a “hold” rating and issued a $180.00 price objective on shares of Amgen in a report on Monday, May 22nd. Leerink Swann reissued a “market perform” rating and issued a $161.00 price objective on shares of Amgen in a report on Thursday, June 22nd. Credit Suisse Group set a $177.00 price objective on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, UBS AG set a $180.00 price objective on Amgen and gave the company a “hold” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and a consensus target price of $186.04.

Amgen (NASDAQ AMGN) traded up 1.54% during mid-day trading on Thursday, hitting $181.13. The stock had a trading volume of 2,166,555 shares. The stock has a market cap of $132.17 billion, a price-to-earnings ratio of 16.50 and a beta of 1.35. The stock’s 50-day moving average price is $173.69 and its 200-day moving average price is $168.62. Amgen has a 12 month low of $133.64 and a 12 month high of $184.21.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $2.84 earnings per share. On average, analysts predict that Amgen will post $12.57 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Reaffirms “Buy” Rating for Amgen Inc. (AMGN)” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/07/oppenheimer-holdings-inc-reaffirms-buy-rating-for-amgen-inc-amgn.html.

Several large investors have recently modified their holdings of AMGN. TrimTabs Asset Management LLC lifted its position in Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its position in Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. American Beacon Advisors Inc. purchased a new position in Amgen during the first quarter worth approximately $106,000. Finally, Phocas Financial Corp. purchased a new position in Amgen during the second quarter worth approximately $110,000. 78.13% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.